"Gliosarcoma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Rare mixed tumors of the brain and rarely the spinal cord which contain malignant neuroectodermal (glial) and mesenchymal components, including spindle-shaped fibrosarcoma cells. These tumors are highly aggressive and present primarily in adults as rapidly expanding mass lesions. They may arise in tissue that has been previously irradiated. (From Br J Neurosurg 1995 Apr;9(2):171-8)
| Descriptor ID |
D018316
|
| MeSH Number(s) |
C04.557.465.625.600.380.400 C04.557.470.670.380.400 C04.557.580.625.600.380.400
|
| Concept/Terms |
Gliosarcoma- Gliosarcoma
- Gliosarcomas
- Glioblastoma with Sarcomatous Component
- Sarcomatous Glioma
- Glioma, Sarcomatous
- Gliomas, Sarcomatous
- Sarcomatous Gliomas
|
Below are MeSH descriptors whose meaning is more general than "Gliosarcoma".
Below are MeSH descriptors whose meaning is more specific than "Gliosarcoma".
This graph shows the total number of publications written about "Gliosarcoma" by people in this website by year, and whether "Gliosarcoma" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 2000 | 1 | 1 | 2 |
| 2006 | 1 | 0 | 1 |
| 2011 | 2 | 0 | 2 |
| 2020 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Gliosarcoma" by people in Profiles.
-
NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma. Cancer. 2020 06 15; 126(12):2821-2828.
-
Brain tumour targeting strategies via coated ferrociphenol lipid nanocapsules. Eur J Pharm Biopharm. 2012 Aug; 81(3):690-3.
-
Serum-stable, long-circulating paclitaxel-loaded colloidal carriers decorated with a new amphiphilic PEG derivative. Int J Pharm. 2012 Apr 15; 426(1-2):231-238.
-
Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma. Neuro Oncol. 2011 Dec; 13(12):1331-8.
-
Treatment of 9L gliosarcoma in rats by ferrociphenol-loaded lipid nanocapsules based on a passive targeting strategy via the EPR effect. Pharm Res. 2011 Dec; 28(12):3189-98.
-
Administration-dependent efficacy of ferrociphenol lipid nanocapsules for the treatment of intracranial 9L rat gliosarcoma. Int J Pharm. 2012 Feb 14; 423(1):55-62.
-
Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group. Neuro Oncol. 2011 Mar; 13(3):317-23.
-
188Re-loaded lipid nanocapsules as a promising radiopharmaceutical carrier for internal radiotherapy of malignant gliomas. Eur J Nucl Med Mol Imaging. 2008 Oct; 35(10):1838-46.
-
Preferential recurrence of a sarcomatous component of a gliosarcoma after boron neutron capture therapy: case report. J Neurooncol. 2006 Jan; 76(2):143-7.
-
Local delivery of doxorubicin for the treatment of malignant brain tumors in rats. Anticancer Res. 2005 Nov-Dec; 25(6B):3825-31.